Indeed, basal tumors express higher levels of the IRF1 transcript than HER2+ and Luminal A/Luminal B tumors, while no significant difference in constitutive DTX3L mRNA expression is observed across the PAM50 breast cancer groups. This evidence concerns the gene ERBB2 and breast carcinoma.